Japan to start OTC sales of emergency contraceptive in February

Daiichi Sankyo announced it will begin over-the-counter sales of the emergency contraceptive Norlevo on February 2, marking the first time such a pill is available without a prescription in Japan. The pill must be taken in the presence of a trained pharmacist for safety reasons.

Daiichi Sankyo announced on December 18 that it will launch over-the-counter sales of the emergency contraceptive pill Norlevo starting February 2 next year. Produced by Aska Pharmaceutical, the drug received approval from the health ministry in October for OTC availability, making it the first of its kind in Japan without requiring a prescription.

There are no age restrictions on purchasing Norlevo, allowing anyone to buy it. However, for safety, it must be taken under the supervision of a trained pharmacist. The pill is effective in preventing pregnancy in about 80% of cases when taken within 72 hours of intercourse. Its suggested retail price is ¥7,480 per pill.

This move aims to improve access to contraception, offering a new option for women's health management in the country. Key terms include pharmaceuticals, health, pregnancy, and birth control.

Artikel Terkait

Illustration depicting a woman self-screening for medication abortion eligibility using prototype OTC packaging from a JAMA study.
Gambar dihasilkan oleh AI

Studi menemukan banyak pasien dapat melakukan penapisan mandiri untuk kelayakan aborsi medis menggunakan label purwarupa

Dilaporkan oleh AI Gambar dihasilkan oleh AI Fakta terverifikasi

Sebuah studi yang diterbitkan pada 6 April 2026 di JAMA Internal Medicine menemukan bahwa orang yang mencari aborsi medis sering kali mencapai kesimpulan kelayakan yang sama dengan dokter saat menggunakan kemasan purwarupa "gaya obat bebas" (OTC) dan label fakta obat. Para peneliti dan pakar luar mengatakan hasil tersebut menambah bukti bahwa penapisan mandiri dapat berhasil, meskipun langkah apa pun menuju penjualan bebas akan menghadapi hambatan regulasi dan politik yang besar.

Survei nasional baru dan rangkaian kasus paksaan semakin mengintensifkan seruan dari anggota parlemen Republik, jaksa agung negara bagian, dan kelompok advokasi agar FDA memulihkan pengamanan yang lebih ketat pada obat-obatan aborsi—tekanan yang datang bahkan saat pejabat kesehatan federal mengatakan mereka sedang meninjau keamanan mifepristone dan FDA telah menyetujui versi generik kedua.

Dilaporkan oleh AI

Brazil's National Health Surveillance Agency (Anvisa) has approved lenacapavir, sold as Sunlenca, for use as pre-exposure prophylaxis (PrEP) against HIV-1. The drug, given via subcutaneous injection every six months, demonstrated up to 100% efficacy in clinical trials with vulnerable populations. The approval paves the way for regulatory steps that could lead to its availability in the Unified Health System (SUS).

Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.

Dilaporkan oleh AI

The National Economic Prosecutor's Office (FNE) actions to promote competition in the celecoxib anti-inflammatory market led to significant price drops and substantial savings for consumers and the state. Between 2017 and 2024, the drug's price fell 56% in pharmacies and 97% in health services, enabling 11 additional laboratories to enter the market.

Japan is considering revising its anti-prostitution law to include penalties for buyers of sex, aiming to close a loophole that currently only punishes sellers. Justice Minister Hiroshi Hiraguchi announced plans to form an expert panel for discussions this fiscal year. The move addresses growing concerns over street solicitation as a social issue.

Dilaporkan oleh AI

Departemen Kehakiman AS mengajukan mosi pada Jumat untuk menghentikan atau membatalkan gugatan dari Missouri dan negara bagian lain yang dipimpin Republikan yang menantang kebijakan FDA yang mengizinkan mifepristone dikirim melalui pos. Pengajuan tersebut berargumen bahwa melanjutkan kasus akan mengganggu tinjauan keselamatan FDA yang sedang berlangsung terhadap obat itu yang dimulai oleh pemerintahan Trump. Para pendukung pro-hidup telah mengkritik langkah ini, mendesak regulasi yang lebih ketat terhadap aborsi medis.

 

 

 

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak